172 related articles for article (PubMed ID: 35551231)
21. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
22. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma.
Livant DL; Brabec RK; Pienta KJ; Allen DL; Kurachi K; Markwart S; Upadhyaya A
Cancer Res; 2000 Jan; 60(2):309-20. PubMed ID: 10667582
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Chang CJ; Ghosh PK; Hu YF; Brueggemeier RW; Lin YC
Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):293-312. PubMed ID: 8480076
[TBL] [Abstract][Full Text] [Related]
25. Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell marker.
Rubio N; Villacampa MM; El Hilali N; Blanco J
Prostate; 2000 Jul; 44(2):133-43. PubMed ID: 10881023
[TBL] [Abstract][Full Text] [Related]
26. Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma.
Nemoto R; Uchida K; Shimazui T; Hattori K; Koiso K; Harada M
J Urol; 1989 Feb; 141(2):337-40. PubMed ID: 2643726
[TBL] [Abstract][Full Text] [Related]
27. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.
Hafeez BB; Zhong W; Fischer JW; Mustafa A; Shi X; Meske L; Hong H; Cai W; Havighurst T; Kim K; Verma AK
Mol Oncol; 2013 Jun; 7(3):428-39. PubMed ID: 23273564
[TBL] [Abstract][Full Text] [Related]
28. An animal model for the study of prostate carcinoma.
Lubaroff DM; Canfield L; Rasmussen GT; Reynolds CW
Natl Cancer Inst Monogr; 1978 Dec; (49):275-81. PubMed ID: 748781
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
[TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
[TBL] [Abstract][Full Text] [Related]
31. The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model.
Pilat MJ; Lehr JE; Quigley MM; Pienta KJ
Oncol Rep; 1998; 5(4):889-92. PubMed ID: 9625839
[TBL] [Abstract][Full Text] [Related]
32. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Rabbani SA; Harakidas P; Davidson DJ; Henkin J; Mazar AP
Int J Cancer; 1995 Dec; 63(6):840-5. PubMed ID: 8847143
[TBL] [Abstract][Full Text] [Related]
33. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
Bergström M; Lu L; Fasth KJ; Wu F; Bergström-Pettermann E; Tolmachev V; Hedberg E; Cheng A; Långström B
J Nucl Med; 1998 Jul; 39(7):1273-9. PubMed ID: 9669410
[TBL] [Abstract][Full Text] [Related]
34. Generation of metastatic variants by transfection of a rat non-metastatic epithelial cell line with genomic DNA from rat prostatic carcinoma cells.
Ke Y; Beesley C; Smith P; Barraclough R; Rudland P; Foster CS
Br J Cancer; 1998; 77(2):287-96. PubMed ID: 9461000
[TBL] [Abstract][Full Text] [Related]
35. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein.
Blomme EA; Dougherty KM; Pienta KJ; Capen CC; Rosol TJ; McCauley LK
Prostate; 1999 May; 39(3):187-97. PubMed ID: 10334108
[TBL] [Abstract][Full Text] [Related]
36. Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.
Mitsui Y; Sadahira T; Maruyama Y; Wada K; Tanimoto R; Sugimoto M; Araki M; Watanabe M; Yanai H; Watanabe T; Nasu Y
Acta Med Okayama; 2018 Dec; 72(6):605-609. PubMed ID: 30573917
[TBL] [Abstract][Full Text] [Related]
37. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors.
Halin S; Wikström P; Rudolfsson SH; Stattin P; Doll JA; Crawford SE; Bergh A
Cancer Res; 2004 Aug; 64(16):5664-71. PubMed ID: 15313905
[TBL] [Abstract][Full Text] [Related]
38. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis.
Bussemakers MJ; van de Ven WJ; Debruyne FM; Schalken JA
Cancer Res; 1991 Jan; 51(2):606-11. PubMed ID: 1702360
[TBL] [Abstract][Full Text] [Related]
39. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of dunning rat prostate tumor fluid on proliferation of the metastatic MAT-LyLu cell line.
Bugan I; Altun S
Asian Pac J Cancer Prev; 2015; 16(2):831-6. PubMed ID: 25684533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
